Amgen Inc. cash flow to debt ratio of 18.24% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Amgen Inc.'s free cash flow has decreased 22.07% from $10.39B last year to $8.10B, signaling decreasing performance

Amgen Inc.'s debt to equity ratio is 4.90, which means that the company's assets are unhealthy financed, signaling financial risk.

Amgen Inc.'s debt has decreased relative to shareholder equity from 10.23 last year to 4.90 today, signaling strengthened financials

Amgen Inc. has a net debt to EBITDA ratio of 2.69x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Amgen Inc.'s interest coverage ratio of 4.74 indicates that earnings with good margin can cover interest payments on company debt

Amgen Inc.'s profit margin has increased (87.41%) in the last year from 12.24% to 22.93%, signaling increasing performance

Amgen Inc.'s short-term assets of $29.06B exceed its short-term liabilities of $25.49B

Amgen Inc.'s return on assets of 9.14% is higher than the 5.00% threshold, indicating efficient asset utilization

Amgen Inc.'s return on equity of 89.32%, is higher than 15.00%, indicating good performance

Amgen Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Amgen Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Amgen Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Amgen Inc. has a free cash flow yield of 3.60%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Amgen Inc.'s yearly earnings has increased 88.53% since last year from $4.09B to $7.71B, signaling increasing performance

Amgen Inc.'s yearly revenue has increased 9.95% since last year from $33.42B to $36.75B, signaling increasing performance

ROIC 14.22% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Amgen Inc.'s 3-year revenue CAGR of 11.76% is positive, indicating growing revenue over the past 3 years

Amgen Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Amgen Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Amgen Inc. is overvalued relative to its fair value price of 64.08 based on Discounted Cash Flow model

Amgen Inc. has an earnings yield of 3.88%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Amgen Inc. is overvalued relative to its fair value price of 121.37 based on EBITDA multiple model

Amgen Inc. has an EV/EBITDA ratio of 16.02x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Amgen Inc. is undervalued relative to its fair value price of 418.93 based on Earnings Fair Value model

Amgen Inc. has a PEG-ratio over 1 which is considered overvalued

Amgen Inc. has a price-to-book ratio of 19.28x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Amgen Inc. has a price-to-sales ratio of 5.91x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue